drugset / Trial / NCT04718402

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

NCT04718402

Phase 1 Terminated 21 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with advanced gastric carcinoma.

Timeline

Start
2021-03-30
Primary completion
2022-05-30
Completion
2022-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 20 mg/m2 Intravenous

Indications